NCT05688618 · RECRUITING
Effect of the Administration of a Symbiotic (E. Faecium and Agave Inulin) on Mild Cognitive Impairment in Older Adults
This trial is testing whether a symbiotic supplement, combining a probiotic bacteria called Enterococcus faecium with agave inulin (a prebiotic fiber), can improve cognitive function in older adults with mild cognitive impairment. The idea is that a healthier gut microbiome may reduce brain inflammation. This is a Phase NA (feasibility or pilot) trial, meaning it is exploratory and early-stage, not yet proven or approved.
You may qualify if
- Patients with mild cognitive impairment
- Patients who sign the informed consent
You're excluded if
- Patients who do not have mild cognitive impairment
- Patients with advanced cognitive impairment such as Alzheimers disease
- Patients with comorbidities that influence the cognitive functions such as diabetes mellitus, cerebral ischemia or previous brain trauma
- Patients who do not sign the informed consent
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2024-07-30